{"id":"NCT02755649","sponsor":"Regeneron Pharmaceuticals","briefTitle":"A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable","officialTitle":"A Phase 3 Study Investigating the Efficacy, Safety, and Tolerability of Dupilumab Administered to Adult Patients With Severe Atopic Dermatitis Who Are Not Adequately Controlled With or Are Intolerant to Oral Cyclosporine A, or When This Treatment is Not Medically Advisable","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01-31","primaryCompletion":"2017-01-04","completion":"2017-03-31","firstPosted":"2016-04-29","resultsPosted":"2020-08-20","lastUpdate":"2020-08-20"},"enrollment":325,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Dupilumab","otherNames":["DUPIXENT®","REGN668","SAR231893"]},{"type":"DRUG","name":"Matching Placebo","otherNames":[]}],"arms":[{"label":"Placebo QW + TCS","type":"EXPERIMENTAL"},{"label":"Dupilumab 300 mg Q2W + TCS","type":"EXPERIMENTAL"},{"label":"Dupilumab 300 mg QW + TCS","type":"EXPERIMENTAL"}],"summary":"The main objective of the trial is to evaluate the efficacy of 2 dose regimens of dupilumab compared to placebo, administered with concomitant topical corticosteroids (TCS), in adult patients with severe AD who are not adequately controlled with, or are intolerant to, oral Cyclosporine A (CSA), or when this treatment is currently not medically advisable.\n\nThe secondary objective is to assess the safety and tolerability of 2 dose regimens of dupilumab compared to placebo, administered with concomitant TCS, in adult patients with severe AD who are not adequately controlled with, or are intolerant to, oral CSA, or when this treatment is currently not medically advisable.","primaryOutcome":{"measure":"Percentage of Participants With Eczema Area and Severity Index (EASI) 75 (≥75% Improvement From Baseline) at Week 16","timeFrame":"Baseline, Week 16","effectByArm":[{"arm":"Placebo QW + TCS","deltaMin":29.6,"sd":null},{"arm":"Dupilumab 300 mg Q2W + TCS","deltaMin":62.6,"sd":null},{"arm":"Dupilumab 300 mg QW + TCS","deltaMin":59.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"< 0.0001"},{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":73,"countries":["Austria","Belgium","Germany","Ireland","Netherlands","Poland","Russia","Slovakia","Spain","United Kingdom"]},"refs":{"pmids":["36808602","36723913","36525340","34142350","33453450","33165005","31066001","29336016"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":108},"commonTop":["Nasopharyngitis","Dermatitis atopic","Conjunctivitis allergic","Headache","Conjunctivitis"]}}